Unilever Reaches New Settlement in Dry Shampoo Benzene Class Action

Unilever has reached a settlement in principle with US consumers who alleged benzene contamination in its aerosol dry shampoos, reviving a deal months after a federal judge rejected a US$3.6 million proposal.
Lawyers for Unilever and the plaintiffs informed a federal court in Connecticut on 17 November 2026 that both sides had agreed in principle to resolve the class action. The case, filed in 2022, targets aerosol dry shampoos sold under the Dove, TRESemmé, Suave, TIGI, Nexxus and Living Proof brands.
What does the lawsuit allege?
The plaintiffs claim the products contained, or risked containing, benzene — a known carcinogen — without adequate disclosure to consumers. Unilever denies the allegations, and no finding of liability has been made against the company.
Two co-defendants are part of the agreement: Aeropres Corporation and Voyant Beauty. Aeropres supplies propellant, putting aerosol delivery systems at the center of the dispute rather than the shampoo formulations themselves.
Why did the first settlement fail?
A federal judge rejected the earlier proposed settlement, worth roughly US$3.6 million, in February 2026. The court raised concerns about the structure of the proposed settlement class, not the size of the payout.
The parties now have about 60 days to draft a revised settlement agreement and seek preliminary court approval. Financial terms of the new deal have not been disclosed.
What does this mean for aerosol cosmetics?
The litigation underscores the legal and financial exposure manufacturers face when product safety allegations surface in personal care. For brands and their suppliers, the case reinforces the need for:
- Ingredient and propellant testing in aerosol manufacturing
- Robust quality assurance across the supply chain
- Regulatory compliance in volatile-solvent handling
The benzene dry shampoo issue has rippled across the industry since independent testing campaigns began flagging contamination in aerosol products. Cases like this one show how a single contaminant finding can sustain multi-year class litigation even where the defendant admits no fault.
With preliminary approval possibly landing in early 2027, aerosol brands will be watching whether the revised class structure clears the bar that sank the first deal — and what the undisclosed payout says about the true cost of contamination claims.
Source: globalcosmeticsnews.com
Tom Whitfield
Show full bio
Senior reporter covering companies, deals and strategy in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.